12 popular peptides come off the FDA’s “do not compound” list. Here’s what that means
BPC-157, TB-500, GHK-Cu and nine others are no longer on the FDA’s list of risky compounding ingredients. That isn’t the same as approval.
At a glance
- Official record
- FDA list updated April 22, 2026
- Peptides
- BPC-157, LL-37, Dihexa, DSIP, Epitalon, injectable GHK-Cu, KPV, PEG-MGF, Melanotan II, MOTS-c, Semax and TB-500
- Why
- The people who nominated them withdrew their nominations
- Approved now?
- No. A change to an interim list is not drug approval
- Next
- Expert reviews in July 2026, and for the rest by February 2027
The research, explained
The FDA keeps interim lists of raw ingredients that compounding pharmacies want to use. Category 1 ingredients can be used while the FDA reviews them. Category 2 is for ingredients the FDA believes may pose significant safety risks; pharmacies shouldn’t use those.
The FDA’s 2026 records describe the removal of substances from Category 2 after nominators withdrew their nominations. They include BPC-157, TB-500, Melanotan II, MOTS-c, Semax, Epitalon and injectable GHK-Cu.
Removal after a withdrawn nomination does not demonstrate safety or effectiveness and does not amount to approval of a medicine. Compounding eligibility remains subject to the applicable legal requirements.
The FDA scheduled expert reviews for seven of them in July 2026, and for the other five before the end of February 2027.
A later FDA update, dated May 14, distinguishes non-injectable GHK-Cu: that nomination was restored to Category 1 after the nominator clarified that only the injectable nomination was being withdrawn. Route of administration matters.
What does this mean?
The change opened the door to a formal review of these peptides, which is how they could eventually be made by licensed pharmacies.
What don’t we know yet?
None of these peptides has been approved as a medicine, and most have very little human research. Whether any will end up on the allowed list is still undecided.
Watch and learn
These official meetings provide regulatory context for several compounds named in the article. They are historical recordings, not announcements that the compounds were approved.
U.S. Food and Drug Administration
FDA compounding meeting: CJC-1295, AOD-9604 and thymosin alpha-1
The original discussion of these substances and proposed uses. Committee advice is separate from a final regulatory decision.
Official FDA recording · December 4, 2024
Regulatory context
Historical FDA discussion of CJC-1295, AOD-9604 and thymosin alpha-1. An advisory meeting is not approval or evidence of clinical benefit.
U.S. Food and Drug Administration
FDA peptide compounding meeting: July 23, 2026
Full meeting covering BPC-157, KPV, TB-500 and MOTS-c. Advisory discussion is not drug approval.
Official FDA advisory committee recording
Regulatory context
The original July 23, 2026 FDA discussion of BPC-157, KPV, TB-500 and MOTS-c; it documents an advisory review.
U.S. Food and Drug Administration
FDA peptide compounding meeting: July 24, 2026
Full meeting covering DSIP (emideltide), Semax and Epitalon. Advisory discussion is not drug approval.
Official FDA advisory committee recording
Regulatory context
The original July 24, 2026 FDA discussion of DSIP, Semax and Epitalon; it documents an advisory review.
Sources and references
- Bulk drug substances nominated for compounding under Section 503AUS Food and Drug Administration · updated May 14, 2026 (PDF)
- Safety risks and withdrawn compounding nominationsUS Food and Drug Administration · primary safety information
VETUD Learn explains published research in plain language. It is general information, not medical advice. Talk to a doctor before starting, stopping or changing any treatment.
In the research shop
Check the catalog for related laboratory research materials. These products are separate from the approved medicines and clinical trial formulations discussed here.
Checking regional availability…
